Motohiro Tamiya
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 198 publications
EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.
Journal: JTO clinical and research reports
Published: July 28, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 08, 2026
Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.
Journal: Japanese journal of clinical oncology
Published: April 29, 2026
Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.
Journal: JTO clinical and research reports
Published: March 24, 2026
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
Journal: Thoracic cancer
Published: January 31, 2026
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.
Journal: American journal of respiratory and critical care medicine
Published: January 25, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.
Journal: Respiratory medicine
Published: December 24, 2025
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 03, 2025
A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.
Journal: Therapeutic advances in medical oncology
Published: November 24, 2025
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.
Journal: Journal of cachexia, sarcopenia and muscle
Published: November 24, 2025
Last Updated: 09/26/2026